Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published: October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Study links metal exposure to increased risk of atherosclerosis September 18, 2024 Study provides a “bird’s eye view” of the brain and its functions October 27, 2025 Researchers identify a rare genetic change linked to neurodevelopmental disorder September 21, 2026